NCT06537817View on ClinicalTrials.gov

Study to Evaluate HT-4253 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

May 12, 2025

Study Completion Date

May 12, 2025

Conditions
Normal Healthy Subjects
Interventions
DRUG

HT-4253

HT-4253 Single or Multiple doses administered orally as a tablet

DRUG

Placebo

Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
lead

Halia Therapeutics, Inc.

INDUSTRY